<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1058">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857206</url>
  </required_header>
  <id_info>
    <org_study_id>V58_31</org_study_id>
    <secondary_id>U1111-1139-9440</secondary_id>
    <nct_id>NCT01857206</nct_id>
  </id_info>
  <brief_title>Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age</brief_title>
  <official_title>A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Philippines : Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents
      4 to 17 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination.</measure>
    <time_frame>Day 1 to Day 7 after any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events and other indicators of reactogenicity following two doses of either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.</measure>
    <time_frame>Day 1 to Day49 for subjects aged ≥4 To ≤8 years not previously vaccinated. Day 1 to Day 38 for subjects aged ≥4 To ≤8 years previously vaccinated and all subjects aged ≥9 To ≤17 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety was assessed as the number of subjects who reported unsolicited adverse events following vaccination with either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Subjects Reporting Unsolicited Serious Adverse Events After Any Vaccination.</measure>
    <time_frame>Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety was assessed as the number of subjects who reported serious adverse events (SAEs), medically attended AEs and new onset of chronic diseases (NOCD) in subjects aged ≥4 To ≤17 Years.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2055</enrollment>
  <condition>Influenza</condition>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>TIVc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mammalian cell based flu vaccine</intervention_name>
    <arm_group_label>TIVc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg based flu vaccine</intervention_name>
    <arm_group_label>TIVf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Healthy subjects 4-17 years of age

        Exclusion Criteria:

          -  Subjects who are not healthy,

          -  Subjects who are pregnant or breast feeding,

          -  Subjects with a history of severe allergic reaction or allergic to any of the vaccine
             components.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>320, Novartis Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>312, Novartis Investigational Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>313, Novartis Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>305, Novartis Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302, Novartis Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301, Novartis Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>311, Novartis Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>308, Novartis Investigational Site</name>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>317, Novartis Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>309, Novartis Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>314, Novartis Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>319, Novartis Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>310, Novartis Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>318, Novartis Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>315, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303, Novartis Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>100, Novartis Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108, Novartis Investigational Site</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107, Novartis Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104, Novartis Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103, Novartis Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105, Novartis Investigational Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>151, Novartis Investigational Site</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>150, Novartis Investigational Site</name>
      <address>
        <city>Beckenham</city>
        <state>Christchurch</state>
        <zip>8024</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>250, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>251, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>254, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>253, Novartis Investigational Site</name>
      <address>
        <city>Manila</city>
        <state>Ermita</state>
        <zip>1001</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>252, Novartis Investigation Site</name>
      <address>
        <city>Manila</city>
        <state>Sampaloc</state>
        <zip>1001</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201, Novartis Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>Muang</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>200, Novartis Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <state>Rajathevi</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202, Novartis Investigational Site</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Siriraj</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 18, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <firstreceived_results_date>September 18, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>children and adolescents</keyword>
  <keyword>trivalent vaccine</keyword>
  <keyword>cell culture</keyword>
  <keyword>embryonated chicken eggs</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at a total of 34 centers in 5 countries: 18 sites in the US, 6 sites in Australia, 2 sites in New Zealand, 5 sites in the Philippines and 3 sites in Thailand.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>TIVc</title>
          <description>Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
        <group group_id="P2">
          <title>TIVf</title>
          <description>Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1372"/>
                <participants group_id="P2" count="683"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1359"/>
                <participants group_id="P2" count="673"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ADMINISTRATIVE REASON</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TIVc</title>
          <description>Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
        <group group_id="B2">
          <title>TIVf</title>
          <description>Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
        <group group_id="B3">
          <title>TOTAL</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1372"/>
                <measurement group_id="B2" value="683"/>
                <measurement group_id="B3" value="2055"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.1" spread="3.8"/>
                <measurement group_id="B2" value="9.3" spread="3.9"/>
                <measurement group_id="B3" value="9.1" spread="3.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="703"/>
                <measurement group_id="B2" value="349"/>
                <measurement group_id="B3" value="1052"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="669"/>
                <measurement group_id="B2" value="334"/>
                <measurement group_id="B3" value="1003"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination.</title>
        <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events and other indicators of reactogenicity following two doses of either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.</description>
        <time_frame>Day 1 to Day 7 after any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the solicited safety dataset, i.e. the subjects in the exposed population who provided postvaccination solicited safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc (≥4 to ≤8 Years)</title>
            <description>Subjects ≥4 to ≤8 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O2">
            <title>TIVf (≥4 to ≤8 Years)</title>
            <description>Subjects ≥4 to ≤8 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O3">
            <title>TIVc (≥9 to ≤17 Years)</title>
            <description>Subjects ≥9 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O4">
            <title>TIVf (≥9 to ≤17 Years)</title>
            <description>Subjects ≥9 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="688"/>
                  <measurement group_id="O2" value="341"/>
                  <measurement group_id="O3" value="682"/>
                  <measurement group_id="O4" value="341"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination.</title>
            <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events and other indicators of reactogenicity following two doses of either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Local</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="422"/>
                  <measurement group_id="O2" value="202"/>
                  <measurement group_id="O3" value="370"/>
                  <measurement group_id="O4" value="160"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Induration (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="46"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Swelling (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Erythema (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="148"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="72"/>
                  <measurement group_id="O4" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Ecchymosis (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="27"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Pain (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="384"/>
                  <measurement group_id="O2" value="186"/>
                  <measurement group_id="O3" value="356"/>
                  <measurement group_id="O4" value="142"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                  <measurement group_id="O2" value="110"/>
                  <measurement group_id="O3" value="267"/>
                  <measurement group_id="O4" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="39"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113"/>
                  <measurement group_id="O2" value="41"/>
                  <measurement group_id="O3" value="126"/>
                  <measurement group_id="O4" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="54"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="128"/>
                  <measurement group_id="O4" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="109"/>
                  <measurement group_id="O4" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="50"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="99"/>
                  <measurement group_id="O4" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="52"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temperature (≥38°C) (AE)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥40°C (Other Indicator)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of pain and/or fever (Other Indicator)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of pain and/or fever (Other Indicator)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="39"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number Of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.</title>
        <description>Safety was assessed as the number of subjects who reported unsolicited adverse events following vaccination with either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.</description>
        <time_frame>Day 1 to Day49 for subjects aged ≥4 To ≤8 years not previously vaccinated. Day 1 to Day 38 for subjects aged ≥4 To ≤8 years previously vaccinated and all subjects aged ≥9 To ≤17 years.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the unsolicited safety dataset, i.e. the subjects in the exposed population who provided postvaccination unsolicited safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc (≥4 to ≤8 Years)</title>
            <description>Subjects ≥4 to ≤8 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O2">
            <title>TIVf (≥4 to ≤8 Years)</title>
            <description>Subjects ≥4 to ≤8 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O3">
            <title>TIVc (≥9 to ≤17 Years)</title>
            <description>Subjects ≥9 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O4">
            <title>TIVf (≥9 to ≤17 Years)</title>
            <description>Subjects ≥9 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="688"/>
                  <measurement group_id="O2" value="340"/>
                  <measurement group_id="O3" value="681"/>
                  <measurement group_id="O4" value="341"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number Of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.</title>
            <description>Safety was assessed as the number of subjects who reported unsolicited adverse events following vaccination with either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="277"/>
                  <measurement group_id="O2" value="139"/>
                  <measurement group_id="O3" value="158"/>
                  <measurement group_id="O4" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least possibly related AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="32"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number Of Subjects Reporting Unsolicited Serious Adverse Events After Any Vaccination.</title>
        <description>Safety was assessed as the number of subjects who reported serious adverse events (SAEs), medically attended AEs and new onset of chronic diseases (NOCD) in subjects aged ≥4 To ≤17 Years.</description>
        <time_frame>Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the unsolicited safety dataset, i.e. the subjects in the exposed population who provided postvaccination unsolicited safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc (≥4 to ≤8 Years)</title>
            <description>Subjects ≥4 to ≤8 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O2">
            <title>TIVf (≥4 to ≤8 Years)</title>
            <description>Subjects ≥4 to ≤8 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O3">
            <title>TIVc (≥9 to ≤17 Years)</title>
            <description>Subjects ≥9 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
          <group group_id="O4">
            <title>TIVf (≥9 to ≤17 Years)</title>
            <description>Subjects ≥9 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="688"/>
                  <measurement group_id="O2" value="340"/>
                  <measurement group_id="O3" value="681"/>
                  <measurement group_id="O4" value="341"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number Of Subjects Reporting Unsolicited Serious Adverse Events After Any Vaccination.</title>
            <description>Safety was assessed as the number of subjects who reported serious adverse events (SAEs), medically attended AEs and new onset of chronic diseases (NOCD) in subjects aged ≥4 To ≤17 Years.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least possibly related SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AE leading to withdrawal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Medically attended AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="284"/>
                  <measurement group_id="O2" value="139"/>
                  <measurement group_id="O3" value="172"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NOCD</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months for subjects aged ≥4 to ≤8 years previously vaccinated and all subjects aged ≥9 to ≤17 Years 7 months for subjects aged ≥4 to ≤8 years not previously vaccinated.</time_frame>
      <desc>For subjects aged ≥4 to ≤8 years not previously vaccinated AEs collected from day 1 to 7 and day 29 to 35. SAEs, medically attended AEs and NOCD till day 213 For subjects aged ≥4 to ≤8 years previously vaccinated and subjects aged ≥9 to ≤17 Years AEs were collected from day 1 to 7. SAEs, medically attended AEs and NOCD were collected till day 183</desc>
      <group_list>
        <group group_id="E1">
          <title>TIVc(4-8Years )</title>
          <description>Subjects ≥4 to ≤8 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
        <group group_id="E2">
          <title>TIVf(4-8Years )</title>
          <description>Subjects ≥4 to ≤8 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
        <group group_id="E3">
          <title>TIVc(9-17Years )</title>
          <description>Subjects ≥9 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
        <group group_id="E4">
          <title>TIVf(9-17Years )</title>
          <description>Subjects ≥9 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>DENGUE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>PHARYNGOTONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>SINUSITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>ANIMAL SCRATCH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBELLAR ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>VISUAL FIELD DEFECT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ADNEXAL TORSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="545" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="267" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="489" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="220" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="433" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="385" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="159" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>INJECTION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="341"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="688"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="341"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="682"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="341"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
